The neurodegenerative disease therapeutic space has attracted significant venture capital investment from specialized funds focused on brain health and neurology. These investors play a critical role in funding early-stage companies developing novel therapies for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
Major Neurodegeneration-Focused Investment Funds
Dementia Discovery Fund (DDF)
Overview: The Dementia Discovery Fund is a venture capital fund dedicated to investing in novel therapeutics for dementia and neurodegenerative diseases. Established in 2015, it brings together pharmaceutical companies, research institutions, and investors to accelerate the development of disease-modifying treatments.
[Neurocentrx](https://neurocentrx.com) — Novel mechanisms for neurodegeneration
Notable Exits: Multiple portfolio companies have been acquired by major pharmaceutical companies.
SV Health Investors
...
Overview
The neurodegenerative disease therapeutic space has attracted significant venture capital investment from specialized funds focused on brain health and neurology. These investors play a critical role in funding early-stage companies developing novel therapies for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
Major Neurodegeneration-Focused Investment Funds
Dementia Discovery Fund (DDF)
Overview: The Dementia Discovery Fund is a venture capital fund dedicated to investing in novel therapeutics for dementia and neurodegenerative diseases. Established in 2015, it brings together pharmaceutical companies, research institutions, and investors to accelerate the development of disease-modifying treatments.
[Neurocentrx](https://neurocentrx.com) — Novel mechanisms for neurodegeneration
Notable Exits: Multiple portfolio companies have been acquired by major pharmaceutical companies.
SV Health Investors
Overview: SV Health Investors is a healthcare-focused venture capital firm with a significant portfolio in neurology and neurodegeneration. The fund has been investing in the space for over two decades.
Focus Areas:
Alzheimer's disease and Parkinson's disease
Novel drug delivery technologies
Biomarkers and diagnostic development
Gene therapy for neurological disorders
Stage Focus: Seed through Series C
Portfolio Companies:
[Denali Therapeutics](https://denalitherapeutics.com) — LRRK2 and other neurodegeneration targets (IPO 2017)](/therapeutics)
[Axial Therapeutics](https://axialtx.com) — Microbiome-based approaches for neurodegeneration](/therapeutics)
[Ventus Therapeutics](https://ventustx.com) — Novel small molecule approaches
Notable Exits:
Denali Therapeutics IPO (NASDAQ: DNLI)
Multiple acquisitions by pharmaceutical partners
Third Rock Ventures
Overview: Third Rock Ventures is a leading biotech venture capital firm with a strong focus on neurology and neurodegenerative diseases. The fund takes an active role in company building and has launched multiple neurodegeneration-focused companies.
Focus Areas:
Alzheimer's disease and Parkinson's disease
Rare neurological diseases
Novel modality development (gene therapy, RNA therapeutics)
Neuroinflammation targeting
Stage Focus: Company founding through Series B
Portfolio Companies:
[Prothelia](https://prothelia.com) — Novel therapies for neurodegenerative diseases](/companies/prothelia)
Overview: GV, the venture capital arm of Alphabet, has invested in multiple companies developing treatments for neurodegenerative diseases, focusing on innovative approaches and digital health solutions.
Focus Areas:
Digital therapeutics and monitoring
Novel drug delivery systems
AI/ML-driven drug discovery
Cell and gene therapy
Stage Focus: Seed through Series D
Portfolio Companies:
[Calico](https://calicolabs.com) — Longevity and age-related diseases (major investment)](/investment)
[Unity Biotechnology](https://unitybiotechnology.com) — Senolytic therapeutics for age-related diseases
Notable Exits: Multiple portfolio companies through IPO and acquisition
Andreessen Horowitz (a16z)
Overview: Andreessen Horowitz has expanded into biotech and healthcare investments, including companies focused on neurological diseases and brain health.
Focus Areas:
Computational biology and AI-driven drug discovery
[Healx](https://healx.ai) — AI-driven rare disease drug discovery](/companies/healx)
[Recursion Pharmaceuticals](https://recursionpharma.com) — AI-driven drug discovery (NASDAQ: RXRX)
Notable Exits:
Recursion Pharmaceuticals IPO
Multiple M&A transactions
ARCH Venture Partners
Overview: ARCH Venture Partners is one of the leading biotech venture capital firms, with extensive experience in founding and building successful neuroscience companies.
Focus Areas:
Alzheimer's disease and Parkinson's disease
Novel therapeutic modalities
Platform technologies
CNS drug delivery
Stage Focus: Company founding through Series B
Portfolio Companies:
[Denali Therapeutics](https://denalitherapeutics.com) — Founded by ARCH (IPO 2017)](/therapeutics)
[Celsius Therapeutics](https://celsiusrx.com) — Novel approaches for inflammatory diseases](/therapeutics)